FDA Reviews Eisai’s Monthly Maintenance Therapy for Early Alzheimer’s with Leqembi
Last week, the US Food and Drug Administration (FDA) announced the acceptance of an indication...
Company
Bristol Myers Squibb’s Krazati Trial Yields Positive Phase III Results in NSCLC
Last week, Bristol Myers Squibb (BMS; NYSE: BMY) unveiled preliminary results from a Phase III...
China’s CNIPA Upholds Patent for Nobel-Winning CRISPR/Cas9 Gene Editing Technology
The China National Intellectual Property Administration (CNIPA) has upheld a key patent surrounding the CRISPR/Cas9...
Shanghai Unveils Massive Investment Projects and Funds to Boost High-Tech Industries
Shanghai has unleashed a flurry of policy-backed project signings and initiatives, marking a significant boost...
AstraZeneca’s AKT Inhibitor Truqap Approved in Japan for HR+, HER2- Breast Cancer
AstraZeneca (AZ; NASDAQ: AZN), headquartered in the UK, has registered with Japan’s Ministry of Health,...
Kobayashi Pharmaceutical Faces Expanding Scandal Over Contaminated Red Yeast Rice Supplements
Kobayashi Pharmaceutical, based in Japan, is facing a deepening scandal over contaminated red yeast rice...
Beijing’s Changping District and State-owned Capital Firm Launch RMB 20 Billion Healthcare Fund
The Changping district of Beijing municipality has reached an agreement with Beijing State-owned Capital Operation...
Abiomed Recalls Over 66,000 Impella Heart Pumps Due to Serious Injury Risk, FDA Classifies as Class I Event
Johnson & Johnson (J&J, NYSE: JNJ), already embroiled in lawsuits over alleged cancer risks associated...
Shanghai Junshi Biosciences Reports 3.38% YOY Revenue Growth in 2023 Financials
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in...
Shenzhen Hepalink Reports 2023 Revenue Dip Amid Sector Demand Declines
Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399), a leading pharmaceutical company based in China,...
InnoCare Pharma Reports 2023 Revenue Growth and Pipeline Expansion
InnoCare Pharma (HKG: 9969; SHA: 688428), a Beijing-based biotech company, has released its financial report...
Bristol Myers Squibb’s Zeposia Fails to Meet Primary Endpoint in Crohn’s Disease Trial
Bristol Myers Squibb (BMS; NYSE: BMY) has announced that a Phase III study for its...
Regenxbio Reports Stable Visual Acuity Improvements with AbbVie’s Gene Therapy in Wet AMD Trial
Regenxbio (NASDAQ: RGNX), the development partner for AbbVie’s (NYSE: ABBV) gene therapy ABBV-RGX-314, has announced...
Gilead Strikes Deal with Xilio Therapeutics for Tumor-Activated IL-12 Candidate
Gilead Sciences (NASDAQ: GILD) has announced an in-licensing agreement with fellow US biotechnology company Xilio...
Alphamab Oncology Reports 31.12% Revenue Growth in 2023 with Continued R&D Focus
Alphamab Oncology (HKG: 9966), a Chinese biopharmaceutical company, has released its financial performance and business...
Bio-Thera Solutions Reports 54.86% YOY Revenue Growth in 2023, Led by Biosimilar Sales
Bio-Thera Solutions (SHA: 688177), a biopharmaceutical company headquartered in Guangzhou, has announced its financial results...
Broncus Medical Inc. Reports 32% YOY Growth in 2023, Highlighted by Strength in China
Broncus Medical Inc. (HKG: 2216), a provider of precision intervention solutions for lung diseases with...
Jiangsu Hengrui’s SHR-A1921 Earns FDA Fast-Track Status for Platinum-Resistant Ovarian Cancer Therapies
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a distinguished pharmaceutical entity, has announced that it...
Hengrui Pharmaceuticals Advances Clinical Trial for PD-L1 Inhibitor Combo in CLDN18.2 Positive Tumors
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company, has received approval from...
Allergan Aesthetics Launches SKINMEDICA in China, Targeting Booming Skincare Market
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced the market launch of its...